Targeted therapy for metastatic colorectal cancer
- Author(s)
- Price, TJ; Tang, M; Gibbs, P; Haller, DG; Peeters, M; Arnold, D; Segelov, E; Roy, A; Tebbutt, N; Pavlakis, N; Karapetis, C; Burge, M; Shapiro, J;
- Details
- Publication Year 2018,Volume 18,Issue #10,Page 9991-1006
- Journal Title
- Expert Review of Anticancer Therapy
- Publication Type
- Journal Article
- Abstract
- INTRODUCTION: Outcomes in metastatic colorectal cancer are improving, with better understanding and use of targeted therapies. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This article reviews the current evidence for targeted therapies in advanced colorectal cancer, including up-to-date data regarding anti-EGFR and anti-VEGF agents, the relevance of primary tumour location and novel subgroups such as BRAF mutated, HER2 amplified and mismatch-repair deficient cancers. Expert commentary: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. The use of EGFR-targeted antibodies should be restricted to patients with extended RAS wild-type profiles, and there is evidence that they should be further restricted to patients with left-sided tumours. Clinically, mCRC can be divided into subgroups based on RAS, BRAF, HER2 and MMR status, each of which have distinct treatment pathways.
- Publisher
- Taylor&Francis
- Research Division(s)
- Systems Biology And Personalised Medicine
- PubMed ID
- 30019590
- Publisher's Version
- https://doi.org/10.1080/14737140.2018.1502664
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2018-07-23 09:32:18
Last Modified: 2019-08-05 11:37:41